Refine
Language
- English (253)
Has Fulltext
- yes (253)
Is part of the Bibliography
- no (253)
Keywords
- e +-e − Experiments (15)
- Branching fraction (10)
- BESIII (8)
- Particle and Resonance Production (8)
- Charm Physics (6)
- Spectroscopy (6)
- Quarkonium (5)
- Exotics (4)
- Charmed mesons (3)
- Electroweak interaction (3)
- Lepton colliders (3)
- e+-e− Experiments (3)
- Charm physics (2)
- Charmonium (2)
- Electroweak Interaction (2)
- Flavour Physics (2)
- Hadronic decays (2)
- Leptonic, semileptonic & radiative decays (2)
- Particle decays (2)
- QCD (2)
- Radiative decay (2)
- BESIII detector (1)
- Bhabha (1)
- Born cross section (1)
- Born cross section measurement (1)
- Branching fraction measurement (1)
- Branching fractions (1)
- CP violation (1)
- Charm vector (1)
- Charmonium (-like) (1)
- Dark photon (1)
- Dark sector (1)
- Effective form factor (1)
- Electromagnetic form factors (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FOS: Physical sciences (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Helicity amplitude analysis (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Initial state radiation (1)
- Invisible decays (1)
- Neutrinos (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Polarization (1)
- Proton (1)
- Rare decays (1)
- Semi-leptonic decays (1)
- Threshold effect (1)
- Y states (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- dimuon (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- electron-positron collision (1)
- hadron spectroscopy (1)
- hadronic events (1)
- helicity amplitude analysis (1)
- inclusive J/ψ decays (1)
- number of J/ψ events (1)
- tetraquark (1)
- trigger efficiency (1)
- Λ+c baryon (1)
The electromagnetic process is studied with the initial-state-radiation technique using 7.5 fb−1 of data collected by the BESIII experiment at seven energy points from 3.773 to 4.600 GeV. The Born cross section and the effective form factor of the proton are measured from the production threshold to 3.0 GeV/ using the invariant-mass spectrum. The ratio of electric and magnetic form factors of the proton is determined from the analysis of the proton-helicity angular distribution.
Using e+e− collision data at ten center-of-mass energies between 2.644 and 3.080 GeV collected with the BESIII detector at BEPCII and corresponding to an integrated luminosity of about 500 pb−1, we measure the cross sections and effective form factors for the process e+e−→Ξ0Ξ¯0 utilizing a single-tag method. A fit to the cross section of e+e−→Ξ0Ξ¯0 with a pQCD-driven power function is performed, from which no significant resonance or threshold enhancement is observed. In addition, the ratio of cross sections for the processes e+e−→Ξ−Ξ¯+ and Ξ0Ξ¯0 is calculated using recent BESIII measurement and is found to be compatible with expectation from isospin symmetry.
Importance Surgery is a mainstay in the management of hidradenitis suppurativa (HS). Adalimumab is the first drug approved for HS. Objective To investigate the efficacy and safety of adalimumab in combination with wide-excision surgery followed by secondary intention healing. Design, Setting, and Participants The Safety and Efficacy of Adalimumab for Hidradenitis Suppurativa Peri-Surgically (SHARPS) trial was a phase 4, randomized, double-blind, placebo-controlled study of adalimumab in conjunction with surgery. Patients were enrolled in 45 sites across 20 countries from July 18, 2016, to February 2, 2019, with the last patient visit on October 16, 2019. Eligible patients (aged 18-65 years) had moderate to severe HS that required radical surgery in an axillary or inguinal region and had 2 other anatomical regions affected, with 1 or more regions at Hurley stage II or III. Analysis was conducted in November 2019. Interventions Patients were randomized 1:1 to receive continuous adalimumab, 40 mg, or placebo during presurgery (12 weeks), perioperative (2 weeks), and postoperative (10 weeks) periods. Main Outcomes and Measures The primary end point was the proportion of patients achieving HS clinical response across all body regions at week 12. Results Overall, 103 patients were randomized to adalimumab and 103 to matching placebo. Among all patients, 51% (n = 106) were women, 94% (n = 193) were White, and the mean (SD) age was 37.6 (11.3) years. At week 12, significantly more patients receiving adalimumab (49 of 103 [48%]) vs placebo (35 of 103 [34%]; P = .049) achieved HS clinical response across all body regions (treatment difference, 14% [95% CI, 0%-27%]). Treatment-emergent adverse events were reported in 74 of 103 patients (72%) and 69 of 103 patients (67%) in the adalimumab and placebo groups, respectively. No increased risk of postoperative wound infection, complication, or hemorrhage was observed with adalimumab vs placebo. Two deaths occurred in the adalimumab group; neither was considered as having a reasonable possibility of relationship to study drug. Conclusions and Relevance Adalimumab was efficacious in conjunction with wide-excision surgery followed by secondary intention healing, with no need to interrupt treatment prior to surgery. These data support further investigation of adalimumab as an adjuvant therapy to surgery in patients with moderate to severe HS. Trial Registration ClinicalTrials.gov Identifier: NCT02808975